HARROW Business Summary

Harrow, Inc. (HROW) is a leading eyecare pharmaceutical company that generates revenue through the commercialization of a diverse portfolio of branded and compounded ophthalmic prescription products. The company’s business model has strategically transitioned from a legacy focus on pharmaceutical compounding via its ImprimisRx division to a high-margin, branded-product-driven growth engine. Its primary revenue segments include the Branded Ophthalmic Portfolio—anchored by flagship products such as VEVYE (cyclosporine ophthalmic solution), IHEEZO (chloroprocaine hydrochloride ophthalmic gel), and TRIESENCE—and its specialized compounding business. Harrow competes directly with global pharmaceutical giants such as Bausch + Lomb, Alcon, and AbbVie (specifically in the dry eye and surgical anesthesia markets). Within this landscape, Harrow distinguishes itself as a high-velocity, niche-focused disruptor that leverages a specialized sales force and a lean acquisition model to capture market share in underserved or high-demand ophthalmic indications. The company is led by founder Mark L. Baum, who serves as Chairman and Chief Executive Officer; Baum is a serial life sciences entrepreneur who previously founded Eton Pharmaceuticals and Melt Pharmaceuticals. The executive leadership team includes Andrew R. Boll, who serves as President and Chief Financial Officer, and Patrick W. Sullivan, the Chief Commercial Officer, who brings extensive experience from Shire and other global biotechs. Scientific and clinical strategy is overseen by Chief Scientific Officer Dr. Amir H. Shojaei, a veteran in ophthalmic drug development. Harrow’s governance is supported by a high-pedigree Board of Directors, including Dr. Adrienne L. Graves (former CEO of Santen Inc.), Lauren P. Silvernail (former CFO of Evolus), and Perry J. Sternberg (CEO of Corium and former EVP at Shire). Notable institutional backing includes significant positions held by Opaleye Management, BlackRock, and Vanguard, reflecting strong investor confidence in the company’s transition toward a pure-play branded pharmaceutical model.